Abstract
The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 930-934 |
| Number of pages | 5 |
| Journal | Journal of Infectious Diseases |
| Volume | 154 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 1986 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
Cite this
Iontophoresis of vidarabine monophosphate for herpes orolabialis. / Gangarosa, Louis P.; Hill, James M.; Thompson, Barry L.; Leggett, Carol; Rissing, John Peter.
In: Journal of Infectious Diseases, Vol. 154, No. 6, 01.01.1986, p. 930-934.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Iontophoresis of vidarabine monophosphate for herpes orolabialis
AU - Gangarosa, Louis P.
AU - Hill, James M.
AU - Thompson, Barry L.
AU - Leggett, Carol
AU - Rissing, John Peter
PY - 1986/1/1
Y1 - 1986/1/1
N2 - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
AB - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
UR - http://www.scopus.com/inward/record.url?scp=0023020053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023020053&partnerID=8YFLogxK
U2 - 10.1093/infdis/154.6.930
DO - 10.1093/infdis/154.6.930
M3 - Article
VL - 154
SP - 930
EP - 934
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 6
ER -